Eli Lilly Says One-Third of New GLP-1 Pill Patients Choose Foundayo

One-third of new GLP-1 pill patients pick Foundayo, CEO Dave Ricks says, as Lilly breaks ground on a $6.5 billion Houston plant due online by 2030.